SRPT Quote, Financials, Valuation and Earnings

Arrowhead Pharmaceuticals has a net margin of 7.2% compared to Sarepta Therapeutics's net margin of --. Sarepta Therapeutics's return on equity of 12.48% beat Arrowhead Pharmaceuticals's return on equity of --.

Sarepta Therapeutics has a consensus price target of $185.96, signalling upside risk potential of 53.05%. On the other hand Arrowhead Pharmaceuticals has an analysts' consensus of $47.50 which suggests that it could grow by 150.53%. Given that Arrowhead Pharmaceuticals has higher upside potential than Sarepta Therapeutics, analysts believe Arrowhead Pharmaceuticals is more attractive than Sarepta Therapeutics.

Sarepta Therapeutics has a beta of 0.767, which suggesting that the stock is 23.328% less volatile than S&P 500. In comparison Arrowhead Pharmaceuticals has a beta of 0.906, suggesting its less volatile than the S&P 500 by 9.418%.

Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals pays out -- of its earnings as a dividend.

Sarepta Therapeutics quarterly revenues are $467.2M, which are larger than Arrowhead Pharmaceuticals quarterly revenues of --. Sarepta Therapeutics's net income of $33.6M is higher than Arrowhead Pharmaceuticals's net income of -$170.5M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 78.90x while Arrowhead Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 7.45x versus 12.50x for Arrowhead Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals has a net margin of 7.2% compared to Sarepta Therapeutics's net margin of 34.1%. Sarepta Therapeutics's return on equity of 12.48% beat Catalyst Pharmaceuticals's return on equity of 27.81%.

Sarepta Therapeutics has a consensus price target of $185.96, signalling upside risk potential of 53.05%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 50.21%. Given that Sarepta Therapeutics has higher upside potential than Catalyst Pharmaceuticals, analysts believe Sarepta Therapeutics is more attractive than Catalyst Pharmaceuticals.

Sarepta Therapeutics has a beta of 0.767, which suggesting that the stock is 23.328% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.748, suggesting its less volatile than the S&P 500 by 25.213%.

Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

Sarepta Therapeutics quarterly revenues are $467.2M, which are larger than Catalyst Pharmaceuticals quarterly revenues of $128.7M. Sarepta Therapeutics's net income of $33.6M is lower than Catalyst Pharmaceuticals's net income of $43.9M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 78.90x while Catalyst Pharmaceuticals's PE ratio is 18.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 7.45x versus 5.68x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 7.2% compared to Sarepta Therapeutics's net margin of 8.48%. Sarepta Therapeutics's return on equity of 12.48% beat Eli Lilly and's return on equity of 66.4%.

Sarepta Therapeutics has a consensus price target of $185.96, signalling upside risk potential of 53.05%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 25.65%. Given that Sarepta Therapeutics has higher upside potential than Eli Lilly and, analysts believe Sarepta Therapeutics is more attractive than Eli Lilly and.

Sarepta Therapeutics has a beta of 0.767, which suggesting that the stock is 23.328% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.30 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sarepta Therapeutics quarterly revenues are $467.2M, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Sarepta Therapeutics's net income of $33.6M is lower than Eli Lilly and's net income of $970.3M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 78.90x while Eli Lilly and's PE ratio is 84.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 7.45x versus 17.33x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 7.2% compared to Sarepta Therapeutics's net margin of 37.71%. Sarepta Therapeutics's return on equity of 12.48% beat Vertex Pharmaceuticals's return on equity of -2.89%.

Sarepta Therapeutics has a consensus price target of $185.96, signalling upside risk potential of 53.05%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $493.61 which suggests that it could grow by 20.76%. Given that Sarepta Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Sarepta Therapeutics is more attractive than Vertex Pharmaceuticals.

Sarepta Therapeutics has a beta of 0.767, which suggesting that the stock is 23.328% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.

Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Sarepta Therapeutics quarterly revenues are $467.2M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Sarepta Therapeutics's net income of $33.6M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Sarepta Therapeutics's price-to-earnings ratio is 78.90x while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 7.45x versus 10.01x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.